Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

Ionis Pharmaceuticals and AstraZeneca said their Phase 3 CARDIO-TTRansform study of eplontersen in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet the primary efficacy endpoint. The negative clinical readout is a material setback for the program’s near-term prospects and could weigh on expectations for future development and valuation.

Analysis

Ionis Pharmaceuticals and AstraZeneca said their Phase 3 CARDIO-TTRansform study of eplontersen in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet the primary efficacy endpoint. The negative clinical readout is a material setback for the program’s near-term prospects and could weigh on expectations for future development and valuation.